Q Yeah. So, so, so break down the state of the art because like embryo screening exists. I think most parents in America, at least if they have the means do some sort of screening, uh, while the embryo is growing, is this purely for IVF? Is this just going a layer deeper? And then is, I want to talk about the regulatory and FDA component as well.
A Let's talk about it. So basically if you go to an IVF clinic today, you're a couple, the vast, vast, vast majority of clinics. The first thing I should understand is that the IVF process is principally controlled today by clinicians or doctors. Honestly, couples don't have as much liberty in our perspective as they should. It's their baby. It's their embryos. They should have the right to those, that information, and they should really pick off any vertical. However, today in the clinic, what generally happens is people test embryos for very rare and severe genetic conditions. For example, like a chromosomal abnormality, like Uh, down syndrome, for example, or even a condition like cystic fibrosis or Tay-Sachs or PKU, right? These are conditions that are very rare, um, that maybe someone might have a carrier for cystic fibrosis, but again, it's, it's pretty rare. Um, then there are conditions that we've all heard of, heard about things like breast cancer, things like coronary artery disease, the things that actually kill the vast majority of people today, right? Chronic conditions kill the vast majority of people today. Those conditions are just not tested for in the clinic, even though we have very good science, actually, that can make those predictions. How do we know this as a, as a DNA company as well? That's what we do, right? We build models that predicts disease and the …
AI assessment note: “instead of just looking for really severe, like down syndrome, cystic fibrosis, why not do breast cancer?”